191 related articles for article (PubMed ID: 957902)
1. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
Goodale DB; Moore KE
Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
[No Abstract] [Full Text] [Related]
2. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Treseder SA; Rose S; Jenner P
Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
[TBL] [Abstract][Full Text] [Related]
3. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
Yoshimine N; Kuzuya F; Mori K; Sakamoto N
Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
[No Abstract] [Full Text] [Related]
4. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Jonkers N; Sarre S; Ebinger G; Michotte Y
J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
[TBL] [Abstract][Full Text] [Related]
6. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
Melamed E; Hefti F; Bitton V; Globus M
Neurology; 1984 Dec; 34(12):1566-70. PubMed ID: 6504328
[TBL] [Abstract][Full Text] [Related]
7. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Johnson RD; Ruthven CR; Goodwin BL; Sandler M
J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
[TBL] [Abstract][Full Text] [Related]
9. The effect of L-dopa and an inhibitor of peripheral decarboxylation on glucose metabolism in brain.
Tyce GM
J Neurochem; 1976 Dec; 27(6):1397-403. PubMed ID: 1003214
[No Abstract] [Full Text] [Related]
10. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
Tayarani-Binazir KA; Jackson MJ; Fisher R; Zoubiane G; Rose S; Jenner P
Eur J Pharmacol; 2010 Jun; 635(1-3):109-16. PubMed ID: 20303948
[TBL] [Abstract][Full Text] [Related]
11. The pharmacology of Parkinson's disease: basic aspects and recent advances.
Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
[TBL] [Abstract][Full Text] [Related]
12. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R
DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
[TBL] [Abstract][Full Text] [Related]
13. L-DOPA exacerbates amphetamine-induced dopamine depletion.
Myers CS; Witten M; Yu YL; Wagner GC
Mol Chem Neuropathol; 1998 Feb; 33(2):81-97. PubMed ID: 9565967
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the effects of reversible and irreversible inhibitors of aromatic L-amino acid decarboxylase on the half-life and other pharmacokinetic parameters of oral L-3,4-dihydroxyphenylalanine.
Huebert ND; Palfreyman MG; Haegele KD
Drug Metab Dispos; 1983; 11(3):195-200. PubMed ID: 6135575
[TBL] [Abstract][Full Text] [Related]
15. Aterial blood pressure in dogs: effects of m-tyrosine alone or in combination with inhibitors of aromatic amino acid decarboxylase; relative hypotensive potencies of L-dopa, DL-m-tyrosine, and L-m-tyrosine.
Minsker DH; Stokes AL
Experientia; 1974 Sep; 30(9):1051-3. PubMed ID: 4412113
[No Abstract] [Full Text] [Related]
16. L-Dopa inhibits prolactin secretion in proestrous rats.
Wiggins JF; Fernstrom JD
Endocrinology; 1977 Aug; 101(2):469-74. PubMed ID: 560295
[TBL] [Abstract][Full Text] [Related]
17. In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats.
Matsushita N; Misu Y; Goshima Y
Eur J Pharmacol; 2009 Mar; 605(1-3):109-13. PubMed ID: 19168057
[TBL] [Abstract][Full Text] [Related]
18. Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET.
Opacka-Juffry J; Ashworth S; Ahier RG; Hume SP
J Neural Transm (Vienna); 1998; 105(4-5):349-64. PubMed ID: 9720967
[TBL] [Abstract][Full Text] [Related]
19. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
Drugs; 1976; 11(5):329-77. PubMed ID: 782834
[No Abstract] [Full Text] [Related]
20. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans.
Polleri A; Masturzo P; Murialdo G; Carolei A
Acta Endocrinol (Copenh); 1980 Jan; 93(1):7-12. PubMed ID: 7355667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]